Abstract
Clozapine, iloperidone, quetiapine, olanzapine, risperidone and ziprasidone represent the new generation of antipsychotic drugs, successors to the typical antipsychotic drugs such as chlorpromazine and haloperidol. The first group of agents are usually referred to as atypical antispychotics because they produce significantly fewer extrapyramidal symptoms than do the typical neuroleptics at clinically equivalent doses. These drugs also show advantages in treating positive symptoms, especially in patients whose positive symptoms fail to respond to the typical antipsychotic drugs. They also have advantages for treating negative symptoms, cognitive dysfunction and mood stabilization. There are variations to the extent to which the atypical antipsychotics show these advantages with regard to efficacy and side effects. The mechanism of action of these drugs is a matter of keen interest. We review here the evidence that some, or all, of these advantages are related to their actions at serotonin and dopamine receptors.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European archives of psychiatry and clinical neuroscience
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.